CD19 News

News

Anti-CD19 CAR-NK Cells Effectively Treat CD-19+ Lymphoma Without Toxicity

09/18/2020

Treatment HLA-mismatched anti-CD19 CAR-NK cells demonstrated promising results without toxic effects in a study of patients with CD-19+ lymphoma.

Treatment HLA-mismatched...

09/18/2020

Oncology

News

Concurrent Ibrutinib and CD19 CAR-T Therapy Well-Tolerated in Relapsed/Refractory CLL

06/16/2020

The administration of CD19 CAR-T cells and concurrent ibrutinib was well-tolerated and yielded high response rates in patients with relapsed or refractory CLL.

The administration of CD19 CAR-T...

06/16/2020

Oncology

News

Responses to Anti-CD19 CAR-T Therapy Tied to Longer Survival in Relapsed CLL

05/14/2020

Study findings suggest that, among patients with relapsed CLL, achieving a complete response after anti-CD19 CAR T-cell infusion is tied to longer OS and PFS, regardless of cell dose.

Study findings suggest that,...

05/14/2020

Oncology

News

CD19 CAR T-Cells With Concurrent Ibrutinib Well-Tolerated in Relapsed/Refractory CLL

02/25/2020

The use of CD19 CAR T-cells with concurrent ibrutinib was well-tolerated and yielded low CRS severity in patients with relapsed or refractory CLL.

The use of CD19 CAR T-cells with...

02/25/2020

Oncology

News

Anti-CD19 CAR-T Therapy Safe, Effective in Large B-Cell Lymphoma

12/05/2018

A follow-up analysis of the ZUMA-1 trial reported 51% of patients receiving axicabtagene ciloleucel were still alive 2 years after treatment.

A follow-up analysis of the...

12/05/2018

Oncology

News

CD19-Targeting CAR-T Therapy Yields Long-Term Response in DLBCL

11/26/2018

In heavily pretreated older adults with relapsed or refractory DLBCL, tisagenlecleucel yielded a high frequency of durable responses, according to study data presented at ASH 2018.

In heavily pretreated older...

11/26/2018

Oncology

News

Exceptional ALL Remission Rates With CD19 CAR T-Cells

09/20/2018

The use of autologous CD19 CAR T-cells led to exceptional remission rates in patients with relapsed and refractory acute lymphoblastic leukemia, according to a recent report.

The use of autologous CD19 CAR...

09/20/2018

Oncology

News

High Rates of Complete Remission in B-Cell Malignancies With CAR T-Cells Cultured Using Faster Technique

06/26/2018

Treatment of patients with relapsed/refractory B-cell malignancies by CAR T-cells cultured using a new technique achieved high complete remission rates.

Treatment of patients with...

06/26/2018

Oncology

News

Correlation of CD19 Expression With Responses and Relapse After CAR-T Therapy

05/24/2018

Chimeric antigen receptor T-cell therapy is effective in a certain group of patients with B-cell acute lymphoblastic leukemia.

Chimeric antigen receptor T-cell...

05/24/2018

Oncology

News

Long-Term Benefits of CD19 CAR-T Therapy in ALL

02/02/2018

Results of a long-term follow-up study show that CAR-T therapy in adults with acute lymphoblastic leukemia may produce durable responses.

Results of a long-term follow-up...

02/02/2018

Oncology

Recent News

News

FDA Approves First-Line Pembrolizumab Plus Chemotherapy for Patients With Unresectable Advanced Malignant Pleural Mesothelioma

09/18/2024

Stephanie Holland ;

Based on results from the KEYNOTE-483 study, the US FDA has approved pembrolizumab plus pemetrexed and platinum-based chemotherapy as first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Based on results from the...

09/18/2024

Oncology

FDA Alerts

FDA Grants Approval to Ribociclib With Aromatase Inhibitor and Letrozole Co-Pack for Adjuvant Treatment of HR-Positive HER2-Negative High-Risk Breast Cancer

09/17/2024

Gina Tomaine ;

On September 17, 2024, the FDA approved ribociclib with an aromatase inhibitor as well as a ribociclib and letrozole co-pack for the adjuvant treatment of adults with hormone receptor-positive, HER2-negative stage II and III early breast...

On September 17, 2024, the FDA...

09/17/2024

Oncology

News

Management of Adverse Events Associated With Selumetinib for Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

09/17/2024

Allison Casey ;

A panel of experts provided consensus recommendations on prevention, early detection, and management of adverse events potentially associated with selumetinib among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

A panel of experts provided...

09/17/2024

Oncology

News

New Risk Stratification Model Provides Prognostic Data on Survival Post-AlloHCT for Older Patients With AML and High-Risk MDS

09/17/2024

Amber Denham ;

The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...

The AML60+ classification system...

09/17/2024

Oncology

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

Conference Coverage

Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

Results from a phase 2 study...

09/10/2024

Oncology